Andelyn is pioneering solutions that turn hope into reality as a biopharmaceutical CDMO. Capabilities span viral vector and vaccine process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and finished drug product manufacturing services located in Columbus, OH USA.

Having 25+ years of experience with viral vector and vaccine manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders with troubleshooting / characterization expertise and GMP material produced for over 75+ worldwide clinical trials. In addition to producing over 400+ cGMP clinical batches and 2000+ research grade productions, Andelyn currently provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing (early 2022), advanced quality systems, full regulatory support, semi-automated to automated fill stations, and supply chain vertical integration.

Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 16+ production suites for customization of new programs and tech transferred programs as of July 2022, offering clinical through commercial-scale capabilities that will help accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients.